Gwo Fuang Ho

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng et al. · Annals of Oncology · 2020 · 233 citations

Hepatology, Medicine, Cancer Management +11

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 174 citations · Full text

Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

Andrew J.S. Coats, Gwo Fuang Ho, Kumar Prabhash et al. · Journal of Cachexia Sarcopenia and Muscle · 2016 · 169 citations · Full text

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

Ainhoa Costas‐Chavarri, Govind Nandakumar, Sarah Temin et al. · Journal of Global Oncology · 2019 · 154 citations · Full text

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Shukui Qin, Zhendong Chen, Weijia Fang et al. · Journal of Clinical Oncology · 2022 · 109 citations

Pharmacotherapy, Pembro Vs Placebo, Pre-clinical Pharmacology +16